SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-24-000038
Filing Date
2024-05-09
Accepted
2024-05-09 16:37:10
Documents
7
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 6-K q12024form6-k.htm 6-K 22445
2 EX-99.1 2024 FIRST QUARTER INTERIM FINANCIAL STATEMENTS ex991-interimfsmarch312024.htm EX-99.1 338502
3 EX-99.2 2024 FIRST QUARTER MD&A ex992-q12024mda.htm EX-99.2 194051
4 EX-99.3 Q1 2024 CERTIFICATION CEO ex993-q12024certificationx.htm EX-99.3 14384
5 EX-99.4 Q1 2024 CERTIFICATION CFO ex994-q12024certificationx.htm EX-99.4 14281
6 oncolyticslogotaglinebluea.jpg GRAPHIC 355294
7 pipeline002.jpg GRAPHIC 639632
  Complete submission text file 0001129928-24-000038.txt   1904684
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 24931393
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)